Therapeutic Effect of Topical 0.125% Atropine in South Korean Myopic Children: A Real-World Experience
Korean Journal of Ophthalmology · 2025
DOI: 10.3341/kjo.2025.0039 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Korean Journal of Ophthalmology, 2025. Verfasst von Dae Hee Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kim's Eye Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Atropine, Refraction, Ocular, Visual Acuity, Myopia. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
To evaluate the effectiveness of 0.125% atropine eye drops in controlling myopia progression by analyzing 1-year follow-up data through a multicenter retrospective study in South Korea.
Methods
A retrospective chart review was conducted across five centers, including 121 myopic children (aged 4–11 years) treated with 0.125% atropine between January 2021 and December 2023. An equal number of age-, sex-, axial length (AL)-, and spherical equivalent (SE)-matched untreated individuals (control group) were included. Baseline and follow-up data at 6 and 12 months included visual acuity, autorefraction, AL measurement (IOLMaster 700), and fundus examination. The primary outcome measures were changes in SE and AL compared to controls.
Results
Age, SE, and AL in the treatment group at baseline were 7.5 ± 1.5 years (range, 4 to 11), –3.07 ± 1.65 diopters (D; range, –0.25 to –5.88 D), and 24.39 ± 0.85 mm (range, 22.19 to 26.94 mm), respectively, and these parameters showed no statistical differences compared to the matched controls. SE after 1-year treatment was less myopic in the treatment group (–3.42 ± 1.72 D vs. –3.94 ± 1.92 D, p = 0.019). Similarly, AL was significantly shorter in treatment group compared to the control group (24.65 ± 0.88 mm vs. 24.88 ± 0.80 mm, p = 0.031). The SE change from baseline was –0.33 ± 0.73 D in the treatment group versus –0.91 ± 1.01 D in the control group (p < 0.001). AL increased by 0.25 ± 0.32 mm in the treatment group, significantly less than 0.49 ± 0.24 mm increase in the control group (p < 0.001). Baseline AL and mean keratometry showed no correlation with AL progression (all p > 0.05).
Conclusions
The use of 0.125% atropine eye drops significantly reduced myopia progression, with approximately 50% reduction in AL elongation compared to controls. Given its effectiveness and variable compliance, 0.125% atropine eye drops may serve as a viable alternative to low-dose atropine for myopia control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Kim's Eye Hospital, Seoul, Korea.
- Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Department of Ophthalmology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea.
- Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.
Zitieren
APA
Kim, D. H., Han, J., Park, K. A., Yang, H. K., Kim, U. S., Kim, S. H., & Paik, H. J. (2025). Therapeutic Effect of Topical 0.125% Atropine in South Korean Myopic Children: A Real-World Experience. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2025.0039
Vancouver
Kim DH, Han J, Park KA, Yang HK, Kim US, Kim SH, et al. Therapeutic Effect of Topical 0.125% Atropine in South Korean Myopic Children: A Real-World Experience. Korean Journal of Ophthalmology. 2025. doi:10.3341/kjo.2025.0039
BibTeX
@article{Kim2025,
author = {Kim, Dae Hee and Han, Jinu and Park, Kyung-Ah and Yang, Hee Kyung and Kim, Ungsoo Samuel and Kim, Seung-Hyun and Paik, Hae Jung},
title = {Therapeutic Effect of Topical 0.125% Atropine in South Korean Myopic Children: A Real-World Experience},
journal = {Korean Journal of Ophthalmology},
year = {2025},
doi = {10.3341/kjo.2025.0039}
}
EUVIMED